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INTRODUCTION 
 
The discovery of antimicrobial agents is considered to be one of the ten great public health 
achievements of the twentieth century. Initially, antibacterials were seen as truly miraculous drugs and 
considered the ‘‘panacea’’ of Medicine, but nowadays the evolution of drug-resistant organisms has 
greatly impaired their therapeutic efficacy. The development of antimicrobial resistance is a naturally 
occurring, multifactorial process that is further accelerated and amplified by misuse of antibacterials. 
The antimicrobial resistance crisis is heightened by the fact that only a limited number of new 
antibacterial drugs have been introduced into the market in the last three decades. 
Antibiotics are one of the most commonly used medicines in hospitals and has substantial share from 
the hospitals’ budget. As their inappropriate use has both medical (increased risk of side-effects, 
therapeutic failure), economic (financial burden) and public health consequences (selection of 
resistance) substantial efforts are needed to rationalise their use. Before designing any interventions 
aiming to optimise antibiotic use, data collection and evaluation is needed to identify problematic fields. 
The use of drugs could be evaluated at general population level and also at individual patient level. 
During my PhD work I intended to follow these steps. 
 
AIMS 
Drug utilization studies  
 
• To analyse the changes in the amount and structure of antibacterial consumption in the hospital 
care sector in Hungary between 1996 and 2007 
• To explore possible regional variations and investigate determinants of antibiotic consumption in 
hospital care in Hungary 
• To show antibiotic related activities of Hungarian adult intensive care units (ICUs) and their 
parent institutes and analyse antibiotic use of Hungarian ICUs (preliminary study). 
 
Pharmacokinetic study 
 
• To analyse the pharmacokinetics and pharmacodynamics of levofloxacin in critically ill patients 
with ventilator-associated pneumonia (VAP) 
• To study the associations between pharmacokinetic and patient-related parameters 
• To evaluate the theoretic pharmacokinetic/pharmacodynamic (PK/PD) appropriateness of different 
levofloxacin regimens. 
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METHODS 
 
Drug utilization studies 
 
All data on systemic antibacterial use (i.e. Anatomical Therapeutic Chemical (ATC) group J01) in 
hospitalized patients were expressed as Defined Daily Dose (DDD) per 100 patient-days. The 2008 
version of the World Health Organization’s ATC/DDD index were used for classifications and 
calculations. Hospital-specific antibiotics were defined, as previously proposed by the European 
Surveillance of Antibiotic Consumption (ESAC) project, as third- and fourth-generation cephalosporins, 
carbapenems, monobactams (note: they have never been marketed in Hungary), aminoglycosides, and 
glycopeptides. 
National and regional level data were originated from the wholesale distribution database of the IMS 
PharmMIS Consulting Company, while antibiotic use in intensive care units were based on dispensing 
data of hospital pharmacy departments. Data on patient-days were based on financial statistics where 
the days of admission and discharge counted together as one patient-day. Trend analysis was used to 
investigate the trends in the national hospital antibiotic utilization through the study period. To 
investigate the determinants for regional differences in hospital antibiotic consumption, we applied a 
multiple linear regression method. Data on independent variables were extracted from the database of 
the Hungarian National Health Fund Administration, Hungarian Central Statistical Office and National 
Institute for Strategic Health Research. The association between hospital and ambulatory care antibiotic 
consumption in Hungarian regions was tested by the Pearson correlation test.  
To assess the antibiotic related activities of Hungarian adult intensive care units (ICUs) and their parent 
institutes a retrospective questionnaire study was performed. After the validation process questionnaires 
were sent to the head of all adult Hungarian ICUs. Both the questionnaire development and the 
evaluation of results were based on the ARPAC (Antibiotic Resistance Prevention and Control) survey. 
To explore differences and study relationships between antibiotic use and certain possible influencing 
factors (e.g. existence of written antibiotic guideline, ICU type, case-mix index) the analysis of 
variances (ANOVA) with Bonferonni post-hoc test or the Pearson correlation analysis was performed, 
as applicable. All statistical analyses were performed with the SPSS program package and P values < 
0.05 were considered as statistically significant. 
 
Pharmacokinetic study 
 
A prospective, open-label study was performed between September 2003 and December 2005 in a 
6-bed neurotrauma ICU. The protocol was previously approved by the local Ethics Committee. Patient 
inclusion criteria were the followings: (a) over 16 years of age; (b) suspected nosocomial VAP, defined 
as a Clinical Pulmonary Infection Score (CPIS) ≥ 6; (c) informed consent obtained from the closest 
relative, (d) normal renal function defined by an estimated creatinine clearance (CLCR) > 50 mL/min, 
based on the Cockroft-Gault formula; (e) presence of intra-arterial and central venous lines in situ.
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Levofloxacin (2×500 mg on the first day and 1×500 mg on consecutive days) was administered as a 1-
hour intravenous infusion. Blood samples were collected at predetermined times, under steady-state 
conditions. The concentrations of free levofloxacin in the plasma were determined by high-pressure 
liquid chromatography (HPLC) after minor in-house modifications and validation of a previously 
developed method. Pharmacokinetic analysis was performed by the WinNonLin; statistical analysis by 
the SPSS program package. The possible association between pharmacokinetic and patient parameters 
was tested by multiple linear regression.  
The pharmacokinetic/pharmacodynamic (PK/PD) appropriateness and the clinical/microbiological 
outcomes of levofloxacin therapy were assessed. Bacterial isolates were identified on species level 
using standard methods. Susceptibility to relevant antibiotics (including levofloxacin) prior to therapy 
was tested by the disc diffusion technique. The minimal inhibitory concentrations (MICs) of the 
different causative pathogens for levofloxacin were determined later, by the E-test method.  
 
RESULTS 
 
National data 
 
The national standardized hospital antibiotic consumption remained relatively stable during the period 
1996-2007 (mean ± standard deviation: 22.0 ± 1.7 DDD per 100 patient-days). In each year hospital-
based antibiotic use accounted for 6.0-8.2 % of the total national consumption. In this section all values 
in the text in parenthesis refer to the two endpoints of the study: 1996 and 2007. 
In 1996 the tetracyclines, from 1997 the penicillin plus beta-lactamase inhibitor combinations (J01CR) 
were the antibacterial group with the highest consumption and co-amoxiclav was the top one antibiotic 
agent (Figure 1). All other penicillins groups displayed a significant drop in use (Table 1). At the first 
part of the study the second-generation cephalosporins accounted for the bulk consumption of 
cephalosporins, while by 2007, the third-generation cephalosporins has played as important role as 
second-generation agents (Table 1). Cefuroxime was the most popular cephalosporin agent through the 
whole study period (Figure 1).  
Carbapenems exhibited a significant increase in use (Table 1), by 2007 the use of meropenem and 
imipenem plus cilastatin were almost identical (0.14 vs. 0.16 DDD per 100 patient-days), while the new 
agent’s, ertapenem role has remained marginal. As concerns glycopeptides, we observed a 3-fold 
increase in the use of vancomycin (0.05 vs. 0.15 DDD per 100 patient-days).  
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Table 1. National consumption of antibiotics in hospitals (DDD/ per 100 patient- days) in 1996 and 
2007 (A) and results of the trend analysis for the 12 years of assessment (B) 
 
 A B 
Antibacterial group 1996 2007 % Changec Rd P value 
J01 Systemic antibacterials 24.14 23.28 -3.56 0.040 0.901 
J01A Tetracyclines 3.80 1.06 -71.96 0.890 <0.001 
J01CA Penicillins with extended spectrum 3.09 0.90 -70.74 0.878 <0.001 
J01CE Beta-lactamase-sensitive penicillins 1.51 0.31 -79.82 0.886 <0.001 
J01CF Beta-lactamase-resistant penicillins 0.03 0.06a 82.73 0.837 0.009 
J01CR Penicillin combinations including 
beta-lactamase inhibitors 3.16 7.32 131.37 0.974 <0.001 
J01DB First-generation cephalosporins 0.24 0.25 5.06 0.257 0.421 
J01DC Second-generation cephalosporins 3.34 1.97 -41.02 0.609 0.036 
J01DD Third-generation cephalosporins 1.02 1.98 95.37 0.928 <0.001 
J01DE Fourth-generation cephalosporins 0.03b 0.04 36.10 0.510 0.161 
J01DH Carbapenems 0.07 0.31 343.45 0.962 <0.001 
J01E Sulfonamides and trimethoprim 1.98 0.70 -64.63 0.929 <0.001 
J01FA Macrolides 1.30 1.68 28.96 0.363 0.246 
J01FF Lincosamides 0.43 0.93 118.47 0.973 <0.001 
J01G Aminoglycoside antibacterials 1.51 0.72 -52.05 0.837 0.001 
J01M Quinolones 2.32 4.17 79.91 0.961 <0.001 
J01XA Glycopeptide antibacterials 0.05 0.19 250.77 0.932 <0.001 
J01XD Imidazole derivatives  0.30 0.44 47.47 0.209 0.515 
Parenteral antibiotics 6.39 7.35 15.02 0.452 0.140 
Hospital specific antibioticse 2.65 3.25 22.64 0.574 0.051 
a: data from 2003 (products were withdrawn from the market in the second half of 2003) , b: data from 1999 
(products are available from 1999); c: percentage change as a percentage of the start value (1996); d: 
correlation coefficient; e: third- and fourth-generation cephalosporins, carbapenems, (monobactams), 
aminoglycosides, and glycopeptides. 
 
The hospital usage of the sulfonamides and tetracyclines fell to one third of the original value, while the 
consumption of aminoglycosides was halved. The fluoroquinolones gained an extended usage in the 
hospital care, its most prominent representative, ciprofloxacin consumption doubled (0.97 vs. 2.36 DDD 
per 100 patient-days). Ofloxacine also showed a considerable use and was among the top 10 
antibacterials until 2006, when a respiratory fluoroquinolone, levofloxacin replaced it in the top-list 
(Figure 1). During the study period, the national hospital use of antibacterials became less colourful: in 
1996 the top-list leader doxycycline was responsible for 15.7% of total hospital antibacterial use, while 
in 2007 the co-amoxiclav shared 30.1 %. 
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Figure 1. The relative share of the top 10 antibacterials from total hospital antibacterial use in Hungary, 
1996-2007 
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Regional differences and their determinants 
 
Despite the stable national standardized hospital antibacterial use, there were large variations depending 
on the region: in each year during the study period (1996-2007), the difference between the regions with 
the lowest and the highest total hospital antibiotic consumption (maximum/minimum ratio) was ranged 
between 1.8 and 2.6. Both at the start and end point of the study, all antibiotic classes showed a large 
interregional variation in their use with a maximum/minimum ratio above two (Table 2). These regional 
differences were also present when the use of different antibacterial classes, parenteral antibacterials or 
hospital-specific antibiotics was considered.  
The pattern of use also differed considerable between the Hungarian regions: the most prominent group, 
the penicillins recorded a relative use between 25.1 % and 49.2 %, second-generation cephalosporins 
between 5.0% and 16.6%, tetracyclines between 2.0 % and 11.3 %, and fluoroquinolones between 
13.9 % and 23.2 % in 2007.  
The heterogeneity of antibiotic use also showed interregional differences: in 1996, the number of active 
agents in the DU90% segment ranged from 17 to 23; while in 2007 it ranged from 13 to 22. In the 
county (Heves) with 13 antibacterials in the DU90 segment in 2007 several antibacterial groups (e.g. 
first-generation cephalosporins, beta-lactamase sensitive penicillin, penicillins with extended spectrum) 
were not represented in the DU90 segment, hence their use were marginal. 
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Table 2. Hospital antibiotic consumption in DDD per 100 patient-days of Hungarian regions (in 1996 and 2007) 
 
1996 2007 
Antibacterial group Mean± SDa Min Max Ratio Max/Min Mean ± SDa Min Max Ratio Max/Min  
J01 Systemic antibacterials 24.24±3.67 15.96 28.24 1.77 21.89±5.79 13.38 34.57 2.58 
J01A Tetracyclines 3.88±0.99 2.27 6.31 2.78 1.04±0.64 0.34 3.13 9.12 
J01CA Penicillins with extended spectrum 3.16±1.42 0.94 6.86 7.28 0.78±0.44 0.18 1.91 10.47 
J01CE Beta-lactamase-sensitive penicillins 1.51±0.72 0.63 3.40 5.35 0.32±0.21 0.06 0.83 14.03 
J01CF Beta-lactamase-resistant penicillins 0.03±0.03 <0.01 0.08 nc b 
J01CR Penicillin combinations including 
beta-lactamase inhibitors 3.04±0.97 1.22 4.95 4.06 6.96±1.82 3.45 10.82 3.14 
J01DB First-generation cephalosporins 0.28±0.16 0.03 0.59 22.88 0.21±0.14 <0.01 0.45 nc 
J01DC Second-generation cephalosporins 3.43±1.17 1.60 6.54 4.10 1.99±1.03 0.63 4.60 7.34 
J01DD Third-generation cephalosporins 1.01±0.48 0.39 2.23 5.78 1.88±0.76 0.69 3.83 5.58 
J01DE Fourth-generation cephalosporins  c 0.04±0.03 <0.01 0.12 nc 
J01DH Carbapenems 0.05±0.06 0.01 0.28 nc 0.23±0.15 0.04 0.59 14.29 
J01E Sulphonamides and trimethoprim 2.05±0.51 1.25 2.97 2.37 0.63±0.23 0.31 1.15 3.65 
J01FA Macrolides 1.28±0.35 0.77 2.22 2.89 1.45±0.64 0.52 2.93 5.58 
J01FF Lincosamides 0.39±0.19 0.06 0.94 16.24 0.84±0.37 0.21 1.75 8.30 
J01G Aminoglycoside antibacterials 1.6±0.49 0.79 2.87 3.61 0.64±0.29 0.16 1.29 8.03 
J01M Quinolones 2.18±0.62 0.94 3.11 3.30 4.01±1.21 2.59 6.77 2.61 
J01XA Glycopeptide antibacterials 0.04±0.03 0.01 0.14 nc 0.15±0.09 0.06 0.33 5.28 
J01XD01Imidazole derivatives  0.30±0.13 0.06 0.54 9.62 0.45±0.2 0.15 0.88 5.74 
Parenteral antibacterials 6.63±1.46 4.25 8.73 2.05 6.98±2.07 3.17 10.86 3.43 
Hospital specific antibacterialsd 2.70±0.78 1.60 4.20 2.63 2.93±1.05 0.96 4.96 5.15 
a: standard deviation.; b: not marketed in 2007; c: not marketed in 1996.; nc: ratio not calculated because of extreme low minimum value (min≤0.01) 
d: third- and fourth-generation cephalosporins, carbapenems, (monobactams), aminoglycosides, and glycopeptides 
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Two models were built in the multiple linear regression: in Model 1 the entered variable was the 
number of reported infections, while in Model 2 the number of reported infections and the case mix 
index (CMI) determined hospital antibiotic use at regional level. Model 1 and Model 2 accounted for 
53 % and 61 % of the observed regional variations in hospital antibiotic consumption, respectively. 
Other variables were excluded from both models: number of beds per 10,000 inhabitants; number of 
patient days per one hospital physician; percentage of active patient-days, percentage of patient-days in 
surgical units; percentage of patient-days in intensive care or infectious disease units; average length of 
stay; percent admitted cases aged 65 years or older and number hospital admissions per 10,000 
inhabitants. 
In the Pearson correlation test, interestingly, total antibiotic consumption in hospitals showed a positive 
and significant association with total antibiotic consumption in ambulatory care (R=0.71, p=0.002). 
 
Antibiotic related activities in Hungarian adult intensive care units and their parent institutes 
 
Responses were received from 60 Hungarian adult ICUs corresponding to a 62% response rate. 
Existence of drug therapy committee and antibiotic committee was reported in 58 (97%) and 23 (38%) 
hospitals, respectively. The involvements of different professions with special role in antibiotic use are 
summarized on Figure 2. 
As concerns antibiotic therapy, multidisciplinary team – involvement of intensive care physician, 
clinical microbiologist/infectologist, hygienist and pharmacist were realized in 7-7 hospitals. In half of 
the hospitals (52%) the frequency of these committee meetings was twice a year or even less frequently. 
 
Figure 2. Constitution of hospital committees 
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Written antibiotic policy and guideline for empiric antibiotic therapy was available in 27 (45%) ICUs. 
These guidelines were worked out in only 13 places (48%) by hospital committees. Pharmacists were 
only indirectly involved in these guideline developments, overall in 11 cases (41%). The four core 
information elements: first choice of drug, recommended dosage, alternative choice and length of 
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therapy were indicated in 27;22;20 and 11 guidelines, respectively. The four core information elements 
together were indicated in 9 guidelines.  
Locally organized education on antibiotic use was performed in 35 ICUs (58%), education on both 
antibiotic use and consequences of resistance development was performed in 26 ICUs (43%) in the two 
years before completing the questionnaire. Pharmacists were involved in 3 cases (9%), pharmaceutical 
companies in 14 cases (40%) of these educational sessions. Continuous education on antibiotic use was 
realized in three ICUs (9%), while the efficacy of education sessions was surveyed in only 4 ICUs 
(11 %). Among the three most useful information sources the microbiology report (45 answers), 
national guidelines (37 answers) and the infectologist’s advice (31 answers) were listed most often, and 
pharmacists were selected only once. Statistics on antibiotic use were performed in 33 units (55%). 
Financial aspects, frequency of antibiotic use, quality of antibiotic use and crude measure of 
quantitative antibiotic use (i.e. number of packages) were surveyed at 22, 20, 15 and 6 ICUs, 
respectively. Standardized antibiotic use expressed in DDD per 100 patient-days was calculated in only 
5 ICUs (8%). Prescribers received personal feed-back on the results of the antibiotic use survey only in 
one ICU. As concerns the ward level activities of pharmacists, we found that they participated in daily 
rounds in none of the units. Most units never (25 answers, 42%) or maximum monthly (23 answers, 
38%) ask the pharmacists about antibiotics. Improvement of antibiotic use is believed to be reached by 
education of doctors (45 answers, 75%). Only 5 units (8%) indicated that involvement of a pharmacist 
might help in rationalising antibiotic use in the future.  
 
Antibiotic use in Hungarian adult intensive care units 
 
Out of the 60 ICUs who participated in the questionnaire survey, 49 were able to provide crude 
antibiotic use data for 2006. During the validation process, 5 ICUs was excluded from the analysis. 
Consumption of systemic antibacterials varied widely, ranging between 27.91 to 167.79 DDD per 100 
patient-days. The proportional use of parenteral agents at Hungarian ICUs ranged between 46.15 to 
98.30 % of total antibacterial use (in average: 81,03%). In surgical ICUs slightly higher total 
antibacterial use and significantly higher parenteral and hospital-specific antibiotic use were detected. 
Significant differences in total, parenteral and hospital-specific antibiotic use were also found between 
ICUs with different category (i.e. level of care) (Figure 3).  
The mean of overall antibiotic use was highest for penicillins with beta-lactamase inhibitors, followed 
by quinolones and third generation cephalosporins (Table 3). Similar ranking were detected in 
interdisciplinary and surgical ICUs. In medical ICUs the consumption of quinolones out-ranged other 
classes of antibacterials (Table 3). Stratification by ICU type also showed differences in the use of 
second generation cephalosporins and glycopeptides which were used in higher quantities in surgical 
ICUs. 
 - 9 - 
Figure 3. Box plot of antibiotic use stratified by ICU type and ICU category 
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In this pooled analysis, none of the elements of antibiotic policy (existence of written antibiotic 
guideline, antibiotic prescribing authority, restricted antibacterials, education on antibiotic use, 
frequency of infectologist consultation) showed to be accompanied by lower antibiotic use.  
Association between antibiotic use in ICUs and the length of stay (R=0.104, P=0.502) or the case-mix 
index (R=0.023, P=0.857) also could not be detected in the correlation analysis. 
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Table 3. Antibiotic consumption in DDD per 100 patient-days in Hungarian ICUs, 2006 
 
 All ICUs Medical Interdisciplinary Surgical 
Antibacterial group Mean±SD Min Max Mean 
J01 Systemic antibacterials 98.69 ±30.88 27.91 167.79 90.60 92.26 113.16 
J01A  Tetracyclines 0.77±1.91 0.00 8.75 0.94 0.90 0.45 
J01CA  Penicillins with extended 
spectrum 2.00±6.08 0.00 38.35 1.79 0.65 5.00 
J01CE  Beta-lactamase sensitive 
penicillins 0.59±1.39 0.00 6.65 0.13 0.71 0.70 
J01CF  Beta-lactamase resistant 
penicillins 0.35±1.16 0.00 5.44 0.00 0.11 1.17 
J01CR  Combinations of penicillins 
including beta-lactamase inhibitors 19.89±8.13 4.07 43.87 15.35 22.45 16.96 
J01DB  First-generation cephalosporins 0.31±0.63 0.00 2.32 0.00 0.24 0.55 
J01DC  Second-generation 
cephalosporins 5.33±7.98 0.00 39.16 3.57 3.16 11.30 
J01DD  Third-generation cephalosporins 15.19±9.44 0.00 40.22 10.24 15.88 15.45 
J01DE  Fourth-generation 
cephalosporins 1.28±1.86 0.00 7.46 1.03 0.90 1.86 
J01DH  Carbapenems 9.46±6.62 0.24 35.90 8.76 8.31 12.02 
J01E  Sulfonamides and trimethoprim 0.94±1.72 0.00 9.22 0.85 1.23 0.41 
J01FA  Macrolides 2.41±3.00 0.00 12.45 1.66 2.80 1.67 
J01FF  Lincosamides 2.57±2.19 0.00 9.58 3.22 2.22 2.39 
J01G  Aminoglycoside antibacterials 6.40±4.91 0.15 19.68 6.56 6.33 6.62 
J01M  Quinolone antibacterials 17.02±9.33 3.27 47.96 22.43 16.38 14.42 
J01XA  Glycopeptide antibacterials 5.57±10.32 0.00 64.42 3.63 3.13 12.35 
J01XD  Imidazole derivatives  8.49±8.38 0.00 44.16 10.45 6.73 9.61 
SD: standard deviation 
 
Pharmacokinetic study 
 
Twelve of the 14 enrolled patients completed the study (Table 4). The primary diagnoses leading to ICU 
admission are listed in Table 5.All patients received levofloxacin as monotherapy, with an average length of 
treatment of 7 days. A high severity of illness (according to the Simplified Acute Physiology Score II), a 
low albumin level and a high estimated creatinine clearance (CLCR) were general characteristics of the 
patient population (Table 4). The mean steady-state levofloxacin plasma concentration–time profile is 
shown in Figure 4, whilst overall pharmacokinetic variables are summarised in Table 4.  
Of the 12 patients with ventilator-associated pneumonia (VAP), 11 had a microbiologically confirmed 
bacteriological aetiology. A total of 14 levofloxacin-sensitive microorganisms were isolated (Table 5). 
Methicillin-sensitive Staphylococcus aureus and Pseudomonas aeruginosa sensitive to most 
antipseudomonal drugs were the most frequent isolates.  
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Table 4. Patient characteristics and steady-state levofloxacin pharmacokinetic parameters following 
intravenous administration of a 500 mg/day maintenance dose to critically ill patients 
Patient parameters (mean ± SD) Pharmacokinetic parameters (mean ± SD) 
Males/Females 7/5 fCmax,ss (mg/L) 8.13 ± 1.64 
Age (years) 40.25 ± 22.01 fCmin,ss (mg/L) 0.48 ± 0.33 
Weight (kg) 72.33 ± 13.34 fVd (L) 82.51 ± 18.93 
SAPS II 40.42 ± 14.93 T1/2β (h) 6.23 ± 1.60 
CLCR (mL/min) 169.63 ± 55.94 CL (mL/min) 178.09 ± 57.98 
Albumin (g/L) 29.08 ± 5.35 fAUC (mg·h/L) 49.63 ± 15.60 
SD: standard deviation; SAPS II: Simplified Acute Physiology Score II, determined on the day of 
admission; CLCR: estimated creatinine clearance based on the Cockcroft–Gault formula; fCmax,ss: maximum 
free plasma concentration at steady state; fCmin,ss: minimum free plasma concentration at steady-state, fVd: 
volume of distribution; T1/2β: elimination half-life; CL: total body levofloxacin clearance; fAUC: steady-
state area under the free plasma concentration−time curve over 24 h. 
 
Figure 4. Mean (±SD) steady-state plasma levofloxacin concentration − time profiles after multiple 
intravenous administration of 500 mg/day to patients with ventilator-associated pneumonia (n=12). 
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CLSI: Clinical and Laboratory Standards Institute; AUC: area under the concentration time curve over 24 h, 
Cmax: maximum plasma concentration; MIC: minimum inhibitory concentration 
 
At the end of levofloxacin therapy, eight patients were completely cured, three patients showed an 
improvement and treatment failed in one patient. Bacterial eradication of the aetiological agent was 
achieved in nine cases. However, in two cases merely a decrease in the number of CFU was observed. 
No superinfection was observed in any of the cases. 
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Table 5. Admission diagnosis, causative pathogens, individual pharmacokinetic and PK/PD parameters and outcome of levofloxacin therapy in critically ill 
patients with ventilator-associated pneumonia 
Outcome Patient 
ID 
Primary 
diagnoses Aetiological agents 
MIC 
(mg/L) 
fCmax,ss 
(mg/L) 
Cmax,ss 
(mg/L) 
fAUC 
(mg h/L) 
AUC 
(mg h/L) Cmax,ss/MIC AUC/MIC 
Clinical Microbiological 
01 SAH N/A N/A 7.68 11.13 41.26 59.80 N/A N/A Improved N/A 
02 T E. coli 0.016 960.05 7465.67 Eradication 
  E. cloacae 0.063 10.60 15.36 82.42 119.45 245.77 1911.21 Failure Eradication 
03 CSI K. pneumoniae 0.125 5.94 8.61 34.87 50.53 68.90 404.26 Cure Eradication 
04 MT P. aeruginosa 0.25 9.54 13.82 67.11 97.26 55.29 389.03 Cure Eradication 
05 MT S. aureus 0.125 79.04 417.10 Eradication 
  S. marcescens 0.125 
6.82 9.88 35.98 52.14 
79.04 417.10 
Improved 
Eradication 
06 MT S. maltophilia 0.25 6.31 9.15 28.28 40.98 36.60 163.93 Cure Failure 
07 BT P. mirabilis 0.063 7.74 11.22 43.16 62.56 179.55 1000.88 Cure Eradication 
08 SAH S. aureus 1 9.55 13.84 61.41 89.00 13.83 89.00 Improved Failure 
09 MT P. aeruginosa 0.25 10.22 14.81 59.73 86.57 59.22 346.28 Cure Eradication 
10 MT S. aureus 1 9.13 68.84 Eradication 
  P. aeruginosa 0.125 
6.30 9.13 47.50 68.84 
73.06 550.75 
Cure 
Eradication 
11 SAH E. coli 0.032 7.62 11.04 41.12 59.59 345.11 1862.27 Cure Eradication 
12 MT Enterobacter spp. 0.25 9.26 13.42 52.68 76.35 53.68 305.41 Cure Eradication 
MIC: minimum inhibitory concentration; fCmax,ss: maximum free plasma concentration at steady-state; Cmax,ss: calculated maximum total plasma concentration 
at steady-state (i.e. after adjusting for 31% protein binding); fAUC: steady-state area under the free plasma concentration−time curve over 24 h; AUC: 
calculated steady-state area under the total plasma concentration−time curve over 24 h (i.e. after adjusting for 31% protein binding); SAH: subarachnoid 
haemorrhage; N/A: not available; T: trauma; CSI: cervical spine injury; MT: multiple trauma; BT: brain tumour. 
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The threshold AUC/MIC for a successful clinical/microbiological outcome of >100–125 was achieved 
in all but two cases. Optimal Cmax/MIC (>10) was attained in 10 of the 11 available cases (Table 5). 
The highest levofloxacin MIC of bacteria that fulfils the minimum AUC/MIC ratio (≥100) for the 
present dosage regimen and with the average pharmacokinetic parameters is 0.72 mg/L. To achieve the 
optimal Cmax/MIC (≥10), the present dosing regimen would allow an MIC of 1.18 both for Gram-
negative and Gram-positive pathogens (Figure 4). Table 6 shows the number of subjects (out of the 12 
patients) with desired PK/PD target achievement at different dedicated MIC values with the 500 mg or 
1000 mg daily levofloxacin regimen. 
 
Table 6. Number of subjects of the 12 critically ill patients achieving desired 
pharmacokinetic/pharmacodynamic targets with 500 mg or 1000 mg daily levofloxacin, considering 
total drug exposurea 
Study MICb Dedicated MIC values Target 
PK/PD 
parameters 0.31 mg/L 0.25 mg/L 0.5 mg/L 1 mg/L 2 mg/Lc 
Cmax/MIC Number of patients achieving the indicated target Cmax/MIC 
10 12 12 12 8 0 
12 12 12 12 5 0 
AUC/MIC Number of patients achieving the indicated target AUC/MIC 
30 12 12 12 12 7 
50 12 12 12 11 1 
100 12 12 11 1 0 
125 12 12 7 0 0 
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Study MICb Dedicated MIC values Target 
PK/PD 
parameters 0.31 mg/L 0.25 mg/L 0.5 mg/L 1 mg/L 2 mg/Lc 
Cmax/MIC Number of patients achieving the indicated target Cmax/MIC 
10 12 12 12 12 8 
12 12 12 12 12 5 
AUC/MIC Number of patients achieving the indicated target AUC/MIC 
30 12 12 12 12 12 
50 12 12 12 12 11 
100 12 12 12 11 1 
125 12 12 12 7 0 
10
00
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250 12 12 7 0 0 
MIC: minimum inhibitory concentration; Cmax: maximum total plasma drug concentration; AUC: 
area under the concentration–time curve; a: desired pharmacokinetic/pharmacodynamic target 
achievement, calculated from the observed individual pharmacokinetic parameters after correction 
for 31% protein binding (i.e. fAUC/0.69 = AUC); b: average MIC of the 14 pathogens isolated in 
this study; c: approved susceptibility breakpoint for levofloxacin. 
 
We observed a weak positive association (R=0.73; P=0.005) between the levofloxacin clearance (CL) 
and the estimated creatinine clearance CLCR. Further relationship between pharmacokinetic parameters 
and patient parameters were not revealed. 
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SUMMARY 
 
My main findings are as follows: 
 
• Total hospital antibiotic consumption in Hungary expressed as DDD per 100 patient-days 
remained relatively stable between 1996 and 2007. Some of the observed changes in the 
pattern of consumption are consistent with the national and international recommendations 
(decreased used of tetracyclines, sulfonamides, and aminoglycosides, increased use of 
respiratory fluoroquinolones), however the low first-generation cephalosporin and narrow 
spectrum penicillin (beta-lactamase sensitive and beta-lactamase resistant penicillins) use as 
well as the less heterogeneous antibacterial use require attention. In international 
comparison, the reason for substantial share of macrolide, lincosamide, fluoroquinolone, 
third-generation cephalosporin and penicillin plus beta-lactamase inhibitor consumption 
from total use should also be addressed in future pharmacoepidemiological studies. 
 
• There were constantly large interregional differences in the Hungarian hospital antibacterial 
consumption. The pattern and heterogeneity of antibacterial use also differed considerable 
between Hungarian regions. The differences in total hospital antibacterial use were 
moderately explained by the number of reported infections and the case mix index (CMI), 
and surprisingly we observed a positive relationship between the regional hospital care and 
ambulatory care antibiotic consumption. All of these may suggest that other determinants 
that could not be explored in this dissertation (e.g. regional prescribing habits or marketing 
practices) may also contribute to regional differences. Therefore future studies should aim at 
collecting data for each individual hospital, as well as data on other possible determinants for 
hospital antibiotic consumption. 
 
• Minimal requirements defined by the Antibiotic Resistance Prevention and Control 
(ARPAC) project have not been fulfilled in many aspects: multidisciplinary hospital 
committees were not realized, and the activity of hospital committees in the antibiotic 
guideline development was not satisfactory. The information content of empiric antibiotic 
guidelines was also deficient. Continuous education and calculation of standardized 
antibiotic use was rare. The role of pharmacist remained marginal in every field. All these 
findings suggest the need for appointment of a responsible, multidisciplinary antibiotic 
management team including a pharmacist.  
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• Consumption of systemic antibacterials varied widely (up to six fold) and the proportional 
use of oral agents also greatly differed at Hungarian adult ICUs. It was difficult to explain 
the quantitative differences; the only factor which showed significant association with total 
antibacterial use was the ICU category (i.e. level of care). However in many Hungarian ICUs 
this was the first time when antibacterial use was expressed in a standardized consumption 
unit. The striking differences in total antibiotic use and high use of oral agents in some ICUs 
– that could not be explained satisfactory in this study – may indicate room for improvement 
in some ICUs and require further analysis.  
 
• Low dose (500 mg per day maintenance dose) intravenous levofloxacin therapy proved to be 
an effective regimen in this limited number of critically ill patients with VAP. The target 
PK/PD thresholds of clinical/microbiological efficacy (AUC/MIC ratio≥100; Cmax/MIC ≥10) 
were exceeded in almost every case. The lack of relationship between Cmax, AUC and patient 
parameters do not allow any prediction for these PK parameters. According to the measured 
pharmacokinetic parameters, the highest safe levofloxacin maintenance dose (1 g/day) would 
ensure optimal PK/PD levels up to an MIC of 1.5 mg/L, which is lower than the currently 
used MIC susceptibility breakpoints for levofloxacin (note: for most pathogens), therefore 
lowering of MIC susceptibility breakpoints for levofloxacin should be considered. 
 
In conclusion, the continuous and close monitoring of antibacterial use at national, regional and local 
level should be considered as an important public-health priority to find problematic areas and trends 
which may require interventions. Also, the determination of optimal dosage in specific patient 
populations (i.e. ICU patients) could help in ensuring clinical/microbiological efficacy.  
 - 16 - 
PUBLICATIONS RELATED TO THE THESIS 
 
I. R Benko, M Matuz, P Doro, R Viola, E Hajdu, DL Monnet, G Soos. Hungarian Hospital Antibiotic 
Consumption at regional level, 1996-2005. Regional hospital antibiotic use in Hungary. Infection 
2009;37(2):133-137.       IF2006: 2.368 
II. Benkı R, Matuz M, Hajdú E, Doró P, Petı Z, Molnár A, Gardi J, Nagy E, Soós G.: [Assesment of 
therapeutic efficacy based on levofloxaxcin plasma level measurement in intensive care unit patients] 
Infektológia és Klinikai Mikrobiológia 2007. XIV. Évf. 3-4. szám, 97-103. 
III. R Benko, M Matuz, P Doro, Z Peto, A Molnar, E Hajdu, E Nagy, J Gardi, G Soos. Pharmacokinetics 
and pharmacodynamics of levofloxacin in critically ill patients with ventilator-associated pneumonia. 
Int J Antimicrob Agents 2007; 30(2):162-8.     IF2006: 2.221 
IV. Benkı R, Matuz M, Doró P, Hajdú E, Nagy G, Nagy E, Soós Gyöngyvér: [Antibiotic consumption 
between 1996 and 2003: national survey and international comparison]. Orv Hetil 2006; 147(26): 1215-
1222. 
V. Benkı R, Matuz M; Hajdú E, Petı Z, Hegedős Á, Bogár L, Soós Gy. [The participation of pharmacist 
in antibiotic related activities of Hungarian hospitals and intensive care units] Acta Pharm Hun  [under 
publication] 
 
VI. R Benko, M Matuz, P Doro, A Nemeth, Z Peto, E Hajdu, L Bogar, Gy Soos.: Antibiotic related 
activities in intensive care units and the involvement of hospital pharmacists. 37th European 
Symposium on Clinical Pharmacy, Dubrovnik, Croatia, 2008 Abs: Pharmacy World & Science 31 (2): 
335-336 
VII. R Benko, M Matuz, P Doro, G Martha, Z Peto, E Hajdu, L Bogar, Gy Soos.: Preliminary results of 
antibiotic use benchmarking survey in Hungarian ICUs. 37th European Symposium on Clinical 
Pharmacy, Dubrovnik, Croatia, 2008 Abs: Pharmacy World & Science 31 (2): 324-324 
VIII. Benkı R, Matuz M, Hajdú E, Dominique M, Soós Gy: A magyarországi ambuláns és kórházi 
antibiotikum felhasználás területi különbségei. A Magyar Infektológiai és Klinikai Mikrobiológiai 
Társaság 36. Kongresszusa. Abs: Infektológia és Klinikai Mikrobiológia XV. Évf. 1. Suppl. S14, 2008 
IX. Benkı R, Matuz M, Hegedős Á, Petı Z, Soós Gy, Bogár L, Hajdú E: Tények és igények a hazai 
intenzív osztályok antibiotikum alkalmazásával kapcsolatban. Magyar Aneszteziológiai és Intenzív 
Terápiás Társaság XXXVI. Kongresszusa, 2008 Abs: Aneszteziológia és Intenzív Terápia 38,S1;EA18, 
2008 
X. Benkı R: Levofloxacin plazmaszint mérésen alapuló terápiás hatáselemzés kritikus állapotú 
betegekben. A Magyar Infektológiai és Klinikai Mikrobiológiai Társaság 2007. évi Pályázatának 
elıadásai és eredményhirdetése, Budapest, 2007 
XI. Benko R, Matuz M, Hajdu E, Peto Z, Molnar A, Gardi J, Nagy E, Soos Gy. Pharmacokinetics of 
intravenous levofloxacin in critically ill patients with ventilator-associated pneumonia 8th Congress of 
Chemotherapy and Infection&4th European Conference on Viral Diseases, Budapest, 2006 
XII. R Benko, M Matuz, P Doro, R Viola, Gy Soos: Hungarian Hospital Antibiotic Consumption. Does It 
Matter Which Measure? 22nd International Conference on Pharmacoepidemiology &Therapeutic Risk 
Management, Lisbon, 2006-11-02. Abs: Pharmacoepidemiology and Drug Safety,15,S1, P614, 2006 
XIII. R Benko M Matuz, E Hajdu, G Nagy, E Nagy, P Doro, A Toth, E Kosik, Gy Soos: Regional 
differences in hospital and community antibiotic consumption in Hungary, ESCP 5th spring conference 
on Clinical Pharmacy, Stockholm, Sweden, 2005 
 
